Vical, Inc. (NASDAQ:VICL)

CAPS Rating: 4 out of 5

The Company researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.


Player Avatar zzlangerhans (99.85) Submitted: 12/17/2012 4:27:24 AM : Underperform Start Price: $2.99 VICL Score: +13.41

Vical has concluded yet again that patients in the phase III trial of Allovectin-7 are living longer than expected, resulting in another lengthy delay before topline data will be released. Naturally, Vical bulls see this as a positive, concluding that it is an indicator that patients are living longer in the treatment arm. That sounds like an old story that I heard earlier this year with Keryx and perifosine, with an unfortunate outcome for the bulls. I believe I've seen similar outcomes from prolonged phase III trials previously, but I can't remember one where the bull thesis turned out to be correct.

I've seen many phase III clinical trials fail against melanoma. It's a bad cancer to bet against and I won't start with Vical.

Featured Broker Partners